Overview
- DarioHealth has surpassed 100 peer-reviewed scientific studies and conference abstracts.
- The research base includes large-scale, longitudinal, independent, and multi-condition studies demonstrating measurable clinical outcomes.
- The milestone strengthens Dario’s position as an evidence-driven digital health partner for employers and health plans.
The News
DarioHealth announced that its research portfolio has surpassed 100 scientific studies, including peer-reviewed journal publications and conference abstracts. The company said the milestone reflects one of the more extensive evidence bases in digital health, supported by large real-world populations, studies lasting up to two years, independent third-party research, and repeated validation of key outcomes.
The research includes directly observed measures such as claims reductions and HbA1c improvements, alongside evaluations spanning cardiometabolic, behavioral health, and musculoskeletal conditions. Dario said the growing body of evidence is increasingly important as employers and health plans shift toward value-based purchasing and demand measurable outcomes beyond engagement metrics or modeled results.
Industry Perspective
As digital health buyers increasingly consolidate vendors and prioritize value-based care, scientific evidence has become a key differentiator. Large-scale, independently validated research can help employers and health plans assess whether digital health solutions deliver durable and repeatable outcomes in real-world populations.
Strategic Impact
The 100-study milestone strengthens DarioHealth’s credibility as an outcomes-driven digital health provider. Its expanding evidence base supports the company’s efforts to deepen relationships with employers and health plans by demonstrating measurable impact across multiple conditions and healthcare outcomes.
Source: PRnewswire
